Summary for Patients from ASH 2017
Greetings and welcome to #MarrowStrong blog!
We’ll be posting a new blog twice a month on the best information for patients and families, and we hope to bring a smile, too!.
We have a lot of events lined up for 2018, planned for you and the #MarrowStrong community:
More than one-fifth of patients undergoing hematopoietic cell transplantation (HCT) reported a lack of awareness of financial burden prior to the procedure, according to research presented at the 59th American Society of Hematology Annual Meeting & Exposition (December 9-12, 2017; Atlanta, GA).
Full article here
Pure red cell aplasia is an orphan disease without rationally established standard therapies. Most cases are idiopathic; a subset is antibody-mediated. There is overlap between idiopathic cases and those with T-large granular lymphocytic leukemia, hypogammaglobulinemia, and low-grade lymphomas. In all these, the pathogenetic mechanisms may involve autoreactive cytotoxic responses.
The relationship between transfusion dependency and health-related quality of life (HRQOL) in patients with
Patients with acute myeloid leukemia (AML) may have genetic mutations in their blood indicating they are at high risk of developing the disease about nine years before diagnosis, according to research from Weill Cornell Medicine and NewYork-Presbyterian investigators. They presented their findings at the 59th annual American Society of Hematology meeting on Dec. 10 in Atlanta, Ga. Full article here